Skip to main content
Home > Week in Review > Deals

Chronological Index of : Deals

 Current Issue
  • Acura, Pfizer deal

    Acura Pharmaceuticals Inc. (NASDAQ:ACUR), Palatine, Ill. Pfizer Inc. (NYSE:PFE), New York, N.Y. Business: Neurology Pfizer returned rights to Oxecta oxycodone to Acura after the biotech terminated a 2007 deal granting …

    Published on 4/21/2014
  • Adimmune Corp., Valneva deal

    Adimmune Corp. (Taiwan:4142), Taichung City, Taiwan Valneva SE (Euronext:VLA; VSE:VLA), Lyon, France Business: Infectious Valneva granted vaccine manufacturer Adimmune rights to develop and commercialize Valneva's …

    Published on 4/21/2014
  • Bio-Rad Laboratories, GnuBIO deal

    Bio-Rad Laboratories Inc. (NYSE:BIO), Hercules, Calif. GnuBIO Inc., Cambridge, Mass. Business: Genomics Tool supplier Bio-Rad acquired GnuBIO for an undisclosed sum. GnuBIO's droplet-based DNA sequencing technology uses…

    Published on 4/21/2014
  • Bio-Techne, Shanghai PrimeGene Bio-Tech Co. deal

    Bio-Techne (NASDAQ:TECH), Minneapolis, Minn. Shanghai PrimeGene Bio-Tech Co., Shanghai, China Business: Supply/Service Bio-Techne's R&D Systems China Co. Ltd. subsidiary will acquire PrimeGene in a cash deal slated to …

    Published on 4/21/2014
  • BioAlliance, Topotarget deal

    BioAlliance Pharma S.A. (Euronext:BIO), Paris, France Topotarget A/S (CSE:TOPO), Copenhagen, Denmark Business: Cancer, Infectious Cancer companies BioAlliance and Topotarget will merge in a stock deal to create a …

    Published on 4/21/2014
  • California Peptide Research Inc., Frontier Scientific Inc. deal

    California Peptide Research Inc., Napa, Calif. Frontier Scientific Inc., Logan, Utah Business: Supply/Service In January, Frontier's Echelon Biosciences Inc. subsidiary acquired California Peptide Research for an …

    Published on 4/21/2014
  • California Stem Cell, NeoStem deal

    California Stem Cell Inc., Irvine, Calif. NeoStem Inc. (NASDAQ:NBS), New York, N.Y. Business: Cancer, Gene/Cell therapy NeoStem will acquire stem cell company California Stem Cell for 5.3 million shares, or about $34.1 …

    Published on 4/21/2014
  • Changchun BCHT, Mucosis deal

    Changchun BCHT Biotechnology Co., Changchun, China Mucosis B.V., Groningen, the Netherlands Business: Infectious Changchun received exclusive, Chinese rights and non-exclusive rights in other undisclosed Asian countries…

    Published on 4/21/2014
  • China National Pharmaceutical Group, Hutchison China deal

    China National Pharmaceutical Group Corp. (Sinopharm), Beijing, China Hutchison China MediTech Ltd. (LSE:HCM), Hong Kong, China Business: Supply/Service Hutchison China MediTech (Chi-Med) said it and Sinopharm's …

    Published on 4/21/2014
  • Clovis, Foundation Medicine deal

    Clovis Oncology Inc. (NASDAQ:CLVS), Boulder, Colo. Foundation Medicine Inc. (NASDAQ:FMI), Cambridge, Mass. Business: Pharmacogenetics Foundation Medicine and Clovis expanded a 2012 deal to develop a companion diagnostic…

    Published on 4/21/2014
  • Epirus, Zalicus deal

    Epirus Biopharmaceuticals Inc., Boston, Mass. Zalicus Inc. (NASDAQ:ZLCS), Cambridge, Mass. Business: Autoimmune, Biosimilars Biosimilar company Epirus will reverse-merge with Zalicus in a stock deal. The combined, …

    Published on 4/21/2014
  • Eternity Healthcare, Kinexus deal

    Eternity Healthcare Inc. (OTCQB:ETAH), Vancouver, B.C. Kinexus Bioinformatics Corp., Vancouver, B.C. Business: Diagnostic Eternity signed a letter of intent to receive an exclusive, worldwide license to protein kinases …

    Published on 4/21/2014
  • Kineta, RLB Holdings deal

    Kineta Inc., Seattle, Wash. RLB Holdings, Greenwich, Conn. Business: Autoimmune Kineta and investment fund RLB formed JV Kineta RLB LLC to develop Kineta compounds, with an initial focus on autoimmune diseases. The …

    Published on 4/21/2014
  • Lead Discovery Center GmbH (LDC), Daiichi Sankyo deal

    Lead Discovery Center GmbH (LDC), Dortmund, Germany Daiichi Sankyo Co. Ltd. (Tokyo:4568), Tokyo, Japan Business: Cancer, Cardiovascular, Endocrine/Metabolic Daiichi and LDC partnered to discover treatments for cancer, …

    Published on 4/21/2014
  • MacroGenics, PolyTherics deal

    MacroGenics Inc. (NASDAQ:MGNX), Rockville, Md. PolyTherics Ltd., London, U.K. Business: Antibodies PolyTherics and MacroGenics extended a 2010 deal to develop antibody-drug conjugates (ADCs). Under the extension, …

    Published on 4/21/2014
  • Moberg Pharma, Oracain ApS deal

    Moberg Pharma AB (SSE:MOB), Bromma, Sweden Oracain ApS, Lyngby, Denmark Business: Neurology Moberg received exclusive worldwide rights to develop and commercialize Oracain's lozenge formulation of bupivacaine to treat …

    Published on 4/21/2014
  • Prosonix, Mylan deal

    Prosonix Ltd., Oxford, U.K. Mylan Inc. (NASDAQ:MYL), Canonsburg, Pa. Business: Inflammation, Generics Mylan received rights to market Prosonix's generic versions of asthma product Flixotide/Flovent from GlaxoSmithKline …

    Published on 4/21/2014
  • Qiagen, CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences deal

    Qiagen N.V. (Xetra:QIA; NASDAQ:QGEN), Venlo, the Netherlands CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria Business: Diagnostic CeMM granted Qiagen an exclusive, …

    Published on 4/21/2014
  • Xencor, Merck deal

    Xencor Inc. (NASDAQ:XNCR), Monrovia, Calif. Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Business: Antibodies Xencor received an undisclosed milestone payment from Merck under a 2013 deal granting the pharma …

    Published on 4/21/2014
  • Albany Molecular Research, Cedarburg Hauser deal

    Albany Molecular Research Inc. (NASDAQ:AMRI), Albany, N.Y. Cedarburg Hauser Pharmaceuticals Inc., Grafton, Wis. Business: Supply/Service Albany Molecular completed its acquisition of contract developer and manufacturer …

    Published on 4/14/2014
  • Alexander David Investments plc, Tiziana Pharma Ltd. deal

    Alexander David Investments plc (LSE:ADI), London, U.K. Tiziana Pharma Ltd., London, U.K. Business: Cancer Alexander David Investments (ADI) will reverse-merge with Tiziana in a deal that values Tiziana at 7.5 million…

    Published on 4/14/2014
  • Ampio, Endo deal

    Ampio Pharmaceuticals Inc. (NYSE-M:AMPE), Greenwood Village, Colo. Endo International plc (NASDAQ:ENDP; TSX:ENL), Dublin, Ireland Business: Genitourinary Ampio's Vyrix Pharmaceutical Inc. subsidiary granted Endo's …

    Published on 4/14/2014
  • Asahi Kasei Pharma, RaQualia deal

    Asahi Kasei Pharma Corp., Tokyo, Japan RaQualia Pharma Inc. (JASDAQ:4579), Aichi, Japan Business: Pharmaceuticals Asahi and RaQualia partnered to discover therapeutic compounds targeting an undisclosed ion channel. The …

    Published on 4/14/2014
  • Aveo Pharmaceuticals, Biodesix deal

    Aveo Pharmaceuticals Inc. (NASDAQ:AVEO), Cambridge, Mass. Biodesix Inc., Broomfield, Colo. Business: Pharmacogenetics The companies partnered to develop and commercialize Biodesix's VeriStrat as a companion diagnostic …

    Published on 4/14/2014
  • Bio-Techne, CyVek deal

    Bio-Techne (NASDAQ:TECH), Minneapolis, Minn. CyVek Inc., Wallingford, Conn. Business: Diagnostic Research supply company Bio-Techne invested $10 million in diagnostics company CyVek for a 20% stake and received the …

    Published on 4/14/2014

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993